Citi opens ‘upside 90-day short-term view’ on West Pharmaceutical

Citi keeps a Buy rating on West Pharmaceutical (WST) with a $300 price target while adding an “upside 90-day short-term view.” The firm views West as one of the stronger margin stories in the space, and sees potential room for upside to consensus earnings estimates this year “when the temporary headwinds are in the rearview.”